Edward George Meloni, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Xenon | 3 | 2025 | 120 | 2.010 |
Why?
|
| Septal Nuclei | 3 | 2024 | 84 | 1.720 |
Why?
|
| Fear | 18 | 2022 | 1494 | 1.610 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 5 | 2024 | 108 | 1.490 |
Why?
|
| Amygdala | 11 | 2024 | 1382 | 1.070 |
Why?
|
| Corticosterone | 2 | 2024 | 301 | 0.980 |
Why?
|
| Corticotropin-Releasing Hormone | 3 | 2007 | 360 | 0.710 |
Why?
|
| Benzazepines | 5 | 2004 | 309 | 0.680 |
Why?
|
| Implosive Therapy | 1 | 2019 | 127 | 0.600 |
Why?
|
| Dopamine Agonists | 4 | 2000 | 353 | 0.580 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2019 | 452 | 0.570 |
Why?
|
| Behavior, Animal | 9 | 2015 | 1879 | 0.570 |
Why?
|
| Receptors, Dopamine D1 | 4 | 2004 | 293 | 0.550 |
Why?
|
| Panic Disorder | 1 | 2019 | 613 | 0.520 |
Why?
|
| Proto-Oncogene Proteins c-fos | 3 | 2015 | 583 | 0.520 |
Why?
|
| Rats, Sprague-Dawley | 22 | 2018 | 8200 | 0.490 |
Why?
|
| Conditioning, Classical | 4 | 2020 | 370 | 0.480 |
Why?
|
| Tranquilizing Agents | 1 | 2014 | 60 | 0.470 |
Why?
|
| Extinction, Psychological | 3 | 2014 | 371 | 0.460 |
Why?
|
| Raphe Nuclei | 2 | 2007 | 105 | 0.460 |
Why?
|
| Cytoskeletal Proteins | 1 | 2018 | 1328 | 0.420 |
Why?
|
| Opioid-Related Disorders | 2 | 2025 | 2189 | 0.410 |
Why?
|
| Rats | 27 | 2020 | 23847 | 0.380 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2022 | 4642 | 0.380 |
Why?
|
| Substantia Nigra | 3 | 2004 | 348 | 0.370 |
Why?
|
| Superior Colliculi | 2 | 2000 | 98 | 0.330 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 2023 | 628 | 0.320 |
Why?
|
| Brain Tissue Transplantation | 1 | 2009 | 81 | 0.320 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2009 | 1143 | 0.320 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2009 | 139 | 0.320 |
Why?
|
| Caudate Nucleus | 2 | 2000 | 392 | 0.300 |
Why?
|
| Neurons | 5 | 2018 | 9524 | 0.290 |
Why?
|
| Anxiety Disorders | 2 | 2009 | 2748 | 0.280 |
Why?
|
| Nerve Tissue Proteins | 2 | 2018 | 4415 | 0.270 |
Why?
|
| Freezing Reaction, Cataleptic | 3 | 2015 | 40 | 0.260 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2005 | 121 | 0.240 |
Why?
|
| Memory | 1 | 2014 | 2210 | 0.230 |
Why?
|
| Muscimol | 3 | 2006 | 70 | 0.230 |
Why?
|
| Social Dominance | 1 | 2024 | 39 | 0.230 |
Why?
|
| GABA Agonists | 3 | 2006 | 106 | 0.220 |
Why?
|
| Reticular Formation | 3 | 2000 | 60 | 0.220 |
Why?
|
| Morphine Dependence | 1 | 2023 | 27 | 0.220 |
Why?
|
| Animals | 38 | 2025 | 169408 | 0.220 |
Why?
|
| Anti-Anxiety Agents | 3 | 2012 | 405 | 0.210 |
Why?
|
| Dopamine Antagonists | 2 | 2004 | 289 | 0.210 |
Why?
|
| Alcohol-Related Disorders | 1 | 2025 | 243 | 0.200 |
Why?
|
| Brain Chemistry | 1 | 2005 | 962 | 0.190 |
Why?
|
| Dopamine | 2 | 2006 | 1617 | 0.190 |
Why?
|
| Affect | 2 | 2007 | 1500 | 0.180 |
Why?
|
| Cochlear Nucleus | 2 | 1998 | 62 | 0.180 |
Why?
|
| Motor Activity | 5 | 2009 | 2722 | 0.180 |
Why?
|
| Stilbamidines | 1 | 2000 | 43 | 0.180 |
Why?
|
| Maze Learning | 4 | 2011 | 484 | 0.170 |
Why?
|
| Levodopa | 1 | 2000 | 223 | 0.170 |
Why?
|
| Anesthetics, Inhalation | 1 | 2025 | 573 | 0.170 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2000 | 151 | 0.170 |
Why?
|
| Receptors, Serotonin | 1 | 2000 | 211 | 0.170 |
Why?
|
| Putamen | 1 | 2000 | 293 | 0.160 |
Why?
|
| Reflex | 1 | 2000 | 375 | 0.150 |
Why?
|
| Nicotinic Agonists | 1 | 2020 | 266 | 0.150 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2011 | 138 | 0.150 |
Why?
|
| Avoidance Learning | 1 | 1999 | 249 | 0.150 |
Why?
|
| Neurotransmitter Agents | 2 | 2015 | 665 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2015 | 10778 | 0.140 |
Why?
|
| Stress, Psychological | 3 | 2024 | 4542 | 0.140 |
Why?
|
| Prefrontal Cortex | 1 | 2007 | 2257 | 0.140 |
Why?
|
| Neuronal Plasticity | 2 | 2018 | 1449 | 0.140 |
Why?
|
| Receptors, Dopamine D2 | 1 | 1999 | 487 | 0.140 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2011 | 501 | 0.130 |
Why?
|
| Infusions, Intraventricular | 1 | 2015 | 31 | 0.130 |
Why?
|
| Excitatory Postsynaptic Potentials | 3 | 2012 | 369 | 0.130 |
Why?
|
| Chlordiazepoxide | 2 | 2012 | 42 | 0.120 |
Why?
|
| Nicotine | 1 | 2020 | 681 | 0.120 |
Why?
|
| Acoustic Stimulation | 4 | 2020 | 1256 | 0.120 |
Why?
|
| Tobacco Use Disorder | 1 | 2020 | 708 | 0.120 |
Why?
|
| Diazepam | 2 | 2012 | 214 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2019 | 905 | 0.110 |
Why?
|
| Male | 31 | 2024 | 365249 | 0.110 |
Why?
|
| Alcoholism | 1 | 2025 | 1981 | 0.110 |
Why?
|
| Cues | 2 | 2020 | 884 | 0.110 |
Why?
|
| Synaptic Transmission | 4 | 2013 | 1177 | 0.110 |
Why?
|
| Bicuculline | 2 | 2004 | 96 | 0.100 |
Why?
|
| GABA Antagonists | 2 | 2004 | 119 | 0.100 |
Why?
|
| Dynorphins | 1 | 2011 | 82 | 0.090 |
Why?
|
| Anxiety | 3 | 2012 | 4677 | 0.090 |
Why?
|
| Receptors, GABA-A | 2 | 2012 | 625 | 0.090 |
Why?
|
| Serotonin | 2 | 2007 | 1045 | 0.080 |
Why?
|
| Brain | 6 | 2015 | 27476 | 0.080 |
Why?
|
| TRPC Cation Channels | 1 | 2009 | 111 | 0.080 |
Why?
|
| Hippocampus | 3 | 2022 | 3786 | 0.080 |
Why?
|
| Social Behavior | 1 | 2015 | 1146 | 0.080 |
Why?
|
| Protein Subunits | 1 | 2012 | 943 | 0.080 |
Why?
|
| Nucleus Accumbens | 1 | 2011 | 373 | 0.080 |
Why?
|
| Long-Term Potentiation | 2 | 2009 | 290 | 0.070 |
Why?
|
| Epinephrine | 1 | 2011 | 794 | 0.070 |
Why?
|
| Veterans | 1 | 2022 | 2672 | 0.070 |
Why?
|
| Exploratory Behavior | 1 | 2009 | 276 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8559 | 0.070 |
Why?
|
| Efferent Pathways | 1 | 2007 | 165 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 22381 | 0.070 |
Why?
|
| Synapses | 2 | 2013 | 1766 | 0.070 |
Why?
|
| Disease | 1 | 2011 | 673 | 0.070 |
Why?
|
| Microinjections | 2 | 2011 | 323 | 0.060 |
Why?
|
| Manganese | 1 | 2008 | 394 | 0.060 |
Why?
|
| Thalamus | 1 | 2011 | 1050 | 0.060 |
Why?
|
| Motivation | 1 | 2015 | 2030 | 0.060 |
Why?
|
| Disease Models, Animal | 7 | 2015 | 18366 | 0.060 |
Why?
|
| Attention | 1 | 2015 | 2425 | 0.060 |
Why?
|
| Auditory Perception | 1 | 2009 | 588 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2010 | 1139 | 0.060 |
Why?
|
| Injections, Intraventricular | 1 | 2004 | 227 | 0.060 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2006 | 298 | 0.060 |
Why?
|
| Mice | 7 | 2024 | 82074 | 0.060 |
Why?
|
| Reward | 1 | 2011 | 985 | 0.060 |
Why?
|
| Colchicine | 1 | 2005 | 257 | 0.060 |
Why?
|
| Self Administration | 2 | 2020 | 388 | 0.050 |
Why?
|
| Gout Suppressants | 1 | 2005 | 177 | 0.050 |
Why?
|
| Learning | 1 | 2013 | 1761 | 0.050 |
Why?
|
| Electromagnetic Fields | 1 | 2005 | 289 | 0.050 |
Why?
|
| Gene Expression Regulation | 4 | 2012 | 11934 | 0.050 |
Why?
|
| Lithium | 1 | 2006 | 600 | 0.050 |
Why?
|
| Emotions | 1 | 2014 | 2768 | 0.050 |
Why?
|
| Nitrogen | 1 | 2023 | 345 | 0.050 |
Why?
|
| Arousal | 1 | 2007 | 1183 | 0.050 |
Why?
|
| Narcotics | 1 | 2023 | 334 | 0.050 |
Why?
|
| Receptors, Serotonin, 5-HT1 | 1 | 2000 | 14 | 0.050 |
Why?
|
| Naltrexone | 1 | 2023 | 319 | 0.050 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2000 | 32 | 0.050 |
Why?
|
| Visual Perception | 1 | 2009 | 1407 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2005 | 5035 | 0.040 |
Why?
|
| Echo-Planar Imaging | 1 | 2005 | 674 | 0.040 |
Why?
|
| Cocaine | 1 | 2006 | 960 | 0.040 |
Why?
|
| Oxidopamine | 1 | 2000 | 173 | 0.040 |
Why?
|
| Genes, fos | 1 | 2000 | 176 | 0.040 |
Why?
|
| Nerve Net | 1 | 2012 | 2361 | 0.040 |
Why?
|
| Electric Stimulation | 3 | 2006 | 1743 | 0.040 |
Why?
|
| Time Factors | 5 | 2015 | 40266 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2020 | 158 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2006 | 2003 | 0.040 |
Why?
|
| Salicylamides | 1 | 1999 | 33 | 0.040 |
Why?
|
| Rats, Long-Evans | 1 | 2020 | 380 | 0.040 |
Why?
|
| Glutamate Decarboxylase | 1 | 2000 | 239 | 0.040 |
Why?
|
| Raclopride | 1 | 1999 | 102 | 0.040 |
Why?
|
| Morphine | 1 | 2023 | 658 | 0.040 |
Why?
|
| Receptors, Metabotropic Glutamate | 2 | 2011 | 196 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 687 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2023 | 591 | 0.040 |
Why?
|
| Escape Reaction | 1 | 1998 | 57 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 1379 | 0.040 |
Why?
|
| Mesencephalon | 1 | 1999 | 339 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2011 | 23652 | 0.040 |
Why?
|
| Habituation, Psychophysiologic | 1 | 1998 | 148 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2000 | 11119 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 1996 | 89 | 0.030 |
Why?
|
| Mammals | 1 | 2022 | 1136 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2000 | 1762 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 7148 | 0.030 |
Why?
|
| Noise | 1 | 1998 | 295 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2011 | 5834 | 0.030 |
Why?
|
| Contrast Media | 1 | 2008 | 5334 | 0.030 |
Why?
|
| Catheterization | 1 | 2000 | 1431 | 0.030 |
Why?
|
| Cochlear Nerve | 1 | 1996 | 202 | 0.030 |
Why?
|
| Light | 1 | 2020 | 1356 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2003 | 1903 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2006 | 877 | 0.030 |
Why?
|
| Adult | 5 | 2023 | 223818 | 0.030 |
Why?
|
| Evoked Potentials, Auditory | 1 | 1996 | 533 | 0.030 |
Why?
|
| Microdissection | 1 | 2013 | 151 | 0.030 |
Why?
|
| Humans | 8 | 2025 | 768887 | 0.030 |
Why?
|
| Choristoma | 1 | 1994 | 205 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2007 | 6740 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 1996 | 947 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2000 | 1933 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2011 | 110 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2013 | 290 | 0.020 |
Why?
|
| Oxygen | 1 | 2023 | 4273 | 0.020 |
Why?
|
| Receptors, Kainic Acid | 1 | 2011 | 91 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2000 | 6242 | 0.020 |
Why?
|
| Adrenergic Agents | 1 | 2011 | 73 | 0.020 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2011 | 81 | 0.020 |
Why?
|
| Alprazolam | 1 | 2010 | 103 | 0.020 |
Why?
|
| GABA Modulators | 1 | 2010 | 109 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 1755 | 0.020 |
Why?
|
| Carbon Tetrachloride | 1 | 2008 | 72 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 3837 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2011 | 738 | 0.020 |
Why?
|
| Pancreas | 1 | 1994 | 1700 | 0.020 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2006 | 55 | 0.020 |
Why?
|
| Sirolimus | 1 | 2013 | 1540 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2012 | 14485 | 0.020 |
Why?
|
| Depression | 1 | 2005 | 8240 | 0.020 |
Why?
|
| Desipramine | 1 | 2005 | 183 | 0.010 |
Why?
|
| Corpus Striatum | 1 | 2011 | 1237 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1996 | 4528 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 2063 | 0.010 |
Why?
|
| Swimming | 1 | 2005 | 210 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1994 | 1483 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2005 | 517 | 0.010 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2005 | 433 | 0.010 |
Why?
|
| Receptors, Dopamine | 1 | 2003 | 296 | 0.010 |
Why?
|
| Female | 2 | 2019 | 397464 | 0.010 |
Why?
|
| Piperidines | 1 | 2011 | 1669 | 0.010 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2005 | 492 | 0.010 |
Why?
|
| Fluoxetine | 1 | 2005 | 735 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2011 | 3120 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 36861 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2003 | 1266 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 1539 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 4042 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3811 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2008 | 2898 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5323 | 0.010 |
Why?
|
| GTP-Binding Protein alpha Subunit, Gi2 | 1 | 1996 | 34 | 0.010 |
Why?
|
| RNA | 1 | 2006 | 2727 | 0.010 |
Why?
|
| Kainic Acid | 1 | 1996 | 203 | 0.010 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 1996 | 142 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1996 | 287 | 0.010 |
Why?
|
| N-Methylaspartate | 1 | 1996 | 231 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 1887 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 4077 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 7472 | 0.010 |
Why?
|
| Auditory Pathways | 1 | 1996 | 238 | 0.010 |
Why?
|
| Neurons, Afferent | 1 | 1996 | 498 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 3446 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14751 | 0.010 |
Why?
|
| Liver | 1 | 2008 | 7579 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 6901 | 0.010 |
Why?
|
| Motor Neurons | 1 | 1996 | 872 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 9564 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1996 | 3588 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 15955 | 0.010 |
Why?
|
| Parkinson Disease | 1 | 2003 | 2896 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 2006 | 5131 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1996 | 3956 | 0.000 |
Why?
|
| Action Potentials | 1 | 1996 | 1838 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1996 | 3744 | 0.000 |
Why?
|
| Binding Sites | 1 | 1996 | 6023 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 13427 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 17629 | 0.000 |
Why?
|
| Cell Line | 1 | 1996 | 15603 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1994 | 13020 | 0.000 |
Why?
|
| Child | 1 | 2006 | 80969 | 0.000 |
Why?
|